5axq - Revision history

OCA at 09:06, 20 March 2024

OCA — Wed, 20 Mar 2024 09:06:15 GMT

←Older revision		Revision as of 09:06, 20 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>		<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.77Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [https://pdbe.org/5axq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [https://www.ebi.ac.uk/pdbsum/5axq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5axq ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [https://pdbe.org/5axq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [https://www.ebi.ac.uk/pdbsum/5axq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5axq ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>		[https://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl)phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER)=6.2) despite the potent PDE10A inhibitory activity (IC50=0.94nM). We performed an optimization study to improve both the P-gp efflux ratio and PDE10A inhibitory activity by utilizing structure-based drug design (SBDD) techniques based on the X-ray crystal structure with PDE10A. Finally, 1-(cyclopropylmethyl)-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyr idazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (19e) was identified with improved P-gp efflux (ER=1.4) and an excellent PDE10A inhibitory activity (IC50=0.080nM). Compound 19e also exhibited satisfactory brain penetration, and suppressed PCP-induced hyperlocomotion with a minimum effective dose of 0.3mg/kg by oral administration in mice.
-
-	Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.,Yoshikawa M, Kamisaki H, Kunitomo J, Oki H, Kokubo H, Suzuki A, Ikemoto T, Nakashima K, Kamiguchi N, Harada A, Kimura H, Taniguchi T Bioorg Med Chem. 2015 Nov 15;23(22):7138-49. doi: 10.1016/j.bmc.2015.10.002. Epub, 2015 Oct 9. PMID:26494583<ref>PMID:26494583</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 5axq" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 06:30, 31 May 2023

OCA — Wed, 31 May 2023 06:30:25 GMT

←Older revision		Revision as of 06:30, 31 May 2023
Line 1:		Line 1:

	==Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold==		==Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold==
-	<StructureSection load='5axq' size='340' side='right' caption='[[5axq]], [[Resolution\|resolution]] 1.77Å' scene=''>	+	<StructureSection load='5axq' size='340' side='right'caption='[[5axq]], [[Resolution\|resolution]] 1.77Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5axp\|5axp]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [https://pdbe.org/5axq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [https://www.ebi.ac.uk/pdbsum/5axq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5axq ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PDE10A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [~~http~~://pdbe.org/5axq PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5axq PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5axq ProSAT]</span></td></tr>	+
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN]] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>	+	[https://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 18:
	</div>		</div>
	<div class="pdbe-citations 5axq" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5axq" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Phosphodiesterase 3D structures\|Phosphodiesterase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: ~~Oki, H~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Zama, Y~~]]	+	[[Category: Oki H]]
-	[[Category: ~~Hydrolase-hydrolase inhibitor complex]]~~	+	[[Category: Zama Y]]
-	~~[[Category: Hydrolase/hydrolase inhibitor~~]]	+

OCA at 13:59, 16 November 2017

OCA — Thu, 16 Nov 2017 13:59:26 GMT

←Older revision		Revision as of 13:59, 16 November 2017
Line 1:		Line 1:
		+
	==Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold==		==Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold==
	<StructureSection load='5axq' size='340' side='right' caption='[[5axq]], [[Resolution\|resolution]] 1.77Å' scene=''>		<StructureSection load='5axq' size='340' side='right' caption='[[5axq]], [[Resolution\|resolution]] 1.77Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5axp\|5axp]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5axp\|5axp]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [http://pdbe.org/5axq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [http://www.ebi.ac.uk/pdbsum/5axq PDBsum]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PDE10A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [http://pdbe.org/5axq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [http://www.ebi.ac.uk/pdbsum/5axq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5axq ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 22:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Oki, H]]		[[Category: Oki, H]]
	[[Category: Zama, Y]]		[[Category: Zama, Y]]
	[[Category: Hydrolase-hydrolase inhibitor complex]]		[[Category: Hydrolase-hydrolase inhibitor complex]]
	[[Category: Hydrolase/hydrolase inhibitor]]		[[Category: Hydrolase/hydrolase inhibitor]]

OCA at 22:16, 30 November 2015

OCA — Mon, 30 Nov 2015 22:16:21 GMT

←Older revision		Revision as of 22:16, 30 November 2015
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold==
		+	<StructureSection load='5axq' size='340' side='right' caption='[[5axq]], [[Resolution\|resolution]] 1.77Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5axq]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AXQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AXQ FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4LK:3-[3-FLUORANYL-4-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]PHENYL]-1,3-OXAZOLIDIN-2-ONE'>4LK</scene>, <scene name='pdbligand=4LP:1-(CYCLOPROPYLMETHYL)-4-FLUORANYL-5-[5-METHOXY-4-OXIDANYLIDENE-3-(2-PHENYLPYRAZOL-3-YL)PYRIDAZIN-1-YL]-3,3-DIMETHYL-INDOL-2-ONE'>4LP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5axp\|5axp]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5axq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5axq OCA], [http://pdbe.org/5axq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5axq RCSB], [http://www.ebi.ac.uk/pdbsum/5axq PDBsum]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN]] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl)phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER)=6.2) despite the potent PDE10A inhibitory activity (IC50=0.94nM). We performed an optimization study to improve both the P-gp efflux ratio and PDE10A inhibitory activity by utilizing structure-based drug design (SBDD) techniques based on the X-ray crystal structure with PDE10A. Finally, 1-(cyclopropylmethyl)-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyr idazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (19e) was identified with improved P-gp efflux (ER=1.4) and an excellent PDE10A inhibitory activity (IC50=0.080nM). Compound 19e also exhibited satisfactory brain penetration, and suppressed PCP-induced hyperlocomotion with a minimum effective dose of 0.3mg/kg by oral administration in mice.

-	~~The entry 5axq is ON HOLD until Paper Publication~~	+	Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.,Yoshikawa M, Kamisaki H, Kunitomo J, Oki H, Kokubo H, Suzuki A, Ikemoto T, Nakashima K, Kamiguchi N, Harada A, Kimura H, Taniguchi T Bioorg Med Chem. 2015 Nov 15;23(22):7138-49. doi: 10.1016/j.bmc.2015.10.002. Epub, 2015 Oct 9. PMID:26494583<ref>PMID:26494583</ref>

-	~~Authors: Oki~~, H.~~, Zama, Y~~.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~Description: Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain~~-~~penetrant PDE10A Inhibitor with 2~~-~~oxindole scaffold~~	+	<div class="pdbe-citations 5axq" style="background-color:#fffaf0;"></div>
-	[[Category: ~~Unreleased Structures~~]]	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Oki, H]]
	[[Category: Zama, Y]]		[[Category: Zama, Y]]
-	[[Category: ~~Oki, H~~]]	+	[[Category: Hydrolase-hydrolase inhibitor complex]]
		+	[[Category: Hydrolase/hydrolase inhibitor]]

OCA at 09:59, 2 September 2015

OCA — Wed, 02 Sep 2015 09:59:36 GMT

←Older revision		Revision as of 09:59, 2 September 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5axq is ON HOLD	+	The entry 5axq is ON HOLD until Paper Publication

	Authors: Oki, H., Zama, Y.		Authors: Oki, H., Zama, Y.

OCA: Protected "5axq" [edit=sysop:move=sysop]

OCA — Wed, 12 Aug 2015 12:25:29 GMT

Protected "5axq" [edit=sysop:move=sysop]

←Older revision

Revision as of 12:25, 12 August 2015

OCA: New page: '''Unreleased structure''' The entry 5axq is ON HOLD Authors: Oki, H., Zama, Y. Description: Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-...

OCA — Wed, 12 Aug 2015 12:25:28 GMT

New page: '''Unreleased structure''' The entry 5axq is ON HOLD Authors: Oki, H., Zama, Y. Description: Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-...

New page

'''Unreleased structure'''

The entry 5axq is ON HOLD

Authors: Oki, H., Zama, Y.

Description: Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold
[[Category: Unreleased Structures]]
[[Category: Zama, Y]]
[[Category: Oki, H]]